Cargando…
Incidence of Antiphospholipid Syndrome: Is Estimation Currently Possible?
Antiphospholipid syndrome is a systemic autoimmune disorder characterized by vascular thrombosis and/or obstetric events in association with persistently elevated antiphospholipid antibodies. Antiphospholipid syndrome is typically considered a rare disease, but the true incidence is uncertain owing...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mesut Onat
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152079/ https://www.ncbi.nlm.nih.gov/pubmed/36880810 http://dx.doi.org/10.5152/eurjrheum.2023.22012 |
_version_ | 1785035679686721536 |
---|---|
author | Ioannou, Yiannis Beukelman, Timothy Murray, Miranda Erkan, Doruk |
author_facet | Ioannou, Yiannis Beukelman, Timothy Murray, Miranda Erkan, Doruk |
author_sort | Ioannou, Yiannis |
collection | PubMed |
description | Antiphospholipid syndrome is a systemic autoimmune disorder characterized by vascular thrombosis and/or obstetric events in association with persistently elevated antiphospholipid antibodies. Antiphospholipid syndrome is typically considered a rare disease, but the true incidence is uncertain owing to the diverse antiphospholipid antibody-related clinical manifestations, inconsistent definitions of antiphospholipid antibody positivity, under-recognition of the disease, and limited population-based studies. Published estimates of the incidence of antiphospholipid syndrome range from approximately 2 to 80 per 100 000 person-years. A targeted literature review and applied methodology were performed to derive a best available estimate. Significant limitations of the published literature were observed, some of which have been previously reported. The incidence of antiphospholipid syndrome in the United States was estimated to be approximately 7.1 to 13.7 per 100 000 person-years in the general population. Although this estimate is likely more accurate than previously reported estimates, large, contemporary, population-based studies that reasonably adhere to the antiphospholipid syndrome classification criteria are needed to further refine estimates of the incidence of antiphospholipid syndrome. |
format | Online Article Text |
id | pubmed-10152079 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Mesut Onat |
record_format | MEDLINE/PubMed |
spelling | pubmed-101520792023-05-03 Incidence of Antiphospholipid Syndrome: Is Estimation Currently Possible? Ioannou, Yiannis Beukelman, Timothy Murray, Miranda Erkan, Doruk Eur J Rheumatol Literature Review Antiphospholipid syndrome is a systemic autoimmune disorder characterized by vascular thrombosis and/or obstetric events in association with persistently elevated antiphospholipid antibodies. Antiphospholipid syndrome is typically considered a rare disease, but the true incidence is uncertain owing to the diverse antiphospholipid antibody-related clinical manifestations, inconsistent definitions of antiphospholipid antibody positivity, under-recognition of the disease, and limited population-based studies. Published estimates of the incidence of antiphospholipid syndrome range from approximately 2 to 80 per 100 000 person-years. A targeted literature review and applied methodology were performed to derive a best available estimate. Significant limitations of the published literature were observed, some of which have been previously reported. The incidence of antiphospholipid syndrome in the United States was estimated to be approximately 7.1 to 13.7 per 100 000 person-years in the general population. Although this estimate is likely more accurate than previously reported estimates, large, contemporary, population-based studies that reasonably adhere to the antiphospholipid syndrome classification criteria are needed to further refine estimates of the incidence of antiphospholipid syndrome. Mesut Onat 2023-01-01 /pmc/articles/PMC10152079/ /pubmed/36880810 http://dx.doi.org/10.5152/eurjrheum.2023.22012 Text en 2023 authors https://creativecommons.org/licenses/by-nc/4.0/ Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. (https://creativecommons.org/licenses/by-nc/4.0/) |
spellingShingle | Literature Review Ioannou, Yiannis Beukelman, Timothy Murray, Miranda Erkan, Doruk Incidence of Antiphospholipid Syndrome: Is Estimation Currently Possible? |
title | Incidence of Antiphospholipid Syndrome: Is Estimation Currently Possible? |
title_full | Incidence of Antiphospholipid Syndrome: Is Estimation Currently Possible? |
title_fullStr | Incidence of Antiphospholipid Syndrome: Is Estimation Currently Possible? |
title_full_unstemmed | Incidence of Antiphospholipid Syndrome: Is Estimation Currently Possible? |
title_short | Incidence of Antiphospholipid Syndrome: Is Estimation Currently Possible? |
title_sort | incidence of antiphospholipid syndrome: is estimation currently possible? |
topic | Literature Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152079/ https://www.ncbi.nlm.nih.gov/pubmed/36880810 http://dx.doi.org/10.5152/eurjrheum.2023.22012 |
work_keys_str_mv | AT ioannouyiannis incidenceofantiphospholipidsyndromeisestimationcurrentlypossible AT beukelmantimothy incidenceofantiphospholipidsyndromeisestimationcurrentlypossible AT murraymiranda incidenceofantiphospholipidsyndromeisestimationcurrentlypossible AT erkandoruk incidenceofantiphospholipidsyndromeisestimationcurrentlypossible |